"Sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu" . "[112FD72DB3AC]" . "Current therapeutic options for multiple myeloma"@en . . "P(NR9489), P(NR9500)" . "1"^^ . . . "15110" . "19" . . "RIV/61989592:15110/09:10224244" . "Sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu"@cs . . "342510" . "Current therapeutic options for multiple myeloma"@en . . . "Sou\u010Dasn\u00FD pohled na st\u00E1le se roz\u0161i\u0159uj\u00EDc\u00ED mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu (MM), kter\u00FD je pod\u00E1n v p\u0159edlo\u017Een\u00E9m sd\u011Blen\u00ED, dokl\u00E1d\u00E1, \u017Ee zejm\u00E9na v posledn\u00ED dek\u00E1d\u011B do\u0161lo k neoby\u010Dejn\u00E9mu pokroku. Zat\u00EDmco v 80. letech minul\u00E9ho stolet\u00ED byl MM r\u016Fzn\u011B rychle progreduj\u00EDc\u00EDm onemocn\u011Bn\u00EDm s n\u00EDzkou kvalitou \u017Eivota pacient\u016F a s d\u00E9lkou p\u0159e\u017Eit\u00ED 2,5-3 roky, v sou\u010Dasnosti m\u00E1 mo\u017Enost dos\u00E1hnout kompletn\u00ED remise p\u0159ibli\u017En\u011B 50 % nemocn\u00FDch s medi\u00E1nem celkov\u00E9ho p\u0159e\u017Eit\u00ED zhruba 5 let a 20 % pacient\u016F s pravd\u011Bpodobnost\u00ED p\u0159e\u017Eit\u00ED del\u0161\u00ED ne\u017E 10 let. Hlub\u0161\u00ED pochopen\u00ED slo\u017Eit\u00E9 biologie MM vneslo do l\u00E9\u010Dby p\u016Fsobky se zcela nov\u00FDm, biologick\u00FDm \u00FA\u010Dinkem (thalidomid, bortezomib a lenalidomid) a s nov\u00FDmi terapeutick\u00FDmi ter\u010Di, zahrnuj\u00EDc\u00EDmi vedle bun\u011B\u010Dn\u00FDch mechanism\u016F i z\u00E1sah do interakc\u00ED n\u00E1dorov\u00FDch bun\u011Bk s mikroprost\u0159ed\u00EDm kostn\u00ED d\u0159en\u011B."@cs . "10"^^ . . "\u0160\u010CUDLA, Vlastimil" . . . "6" . "CZ - \u010Cesk\u00E1 republika" . . . . "Remedia" . . . "Sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu"@cs . . . "Sou\u010Dasn\u00FD pohled na st\u00E1le se roz\u0161i\u0159uj\u00EDc\u00ED mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu (MM), kter\u00FD je pod\u00E1n v p\u0159edlo\u017Een\u00E9m sd\u011Blen\u00ED, dokl\u00E1d\u00E1, \u017Ee zejm\u00E9na v posledn\u00ED dek\u00E1d\u011B do\u0161lo k neoby\u010Dejn\u00E9mu pokroku. Zat\u00EDmco v 80. letech minul\u00E9ho stolet\u00ED byl MM r\u016Fzn\u011B rychle progreduj\u00EDc\u00EDm onemocn\u011Bn\u00EDm s n\u00EDzkou kvalitou \u017Eivota pacient\u016F a s d\u00E9lkou p\u0159e\u017Eit\u00ED 2,5-3 roky, v sou\u010Dasnosti m\u00E1 mo\u017Enost dos\u00E1hnout kompletn\u00ED remise p\u0159ibli\u017En\u011B 50 % nemocn\u00FDch s medi\u00E1nem celkov\u00E9ho p\u0159e\u017Eit\u00ED zhruba 5 let a 20 % pacient\u016F s pravd\u011Bpodobnost\u00ED p\u0159e\u017Eit\u00ED del\u0161\u00ED ne\u017E 10 let. Hlub\u0161\u00ED pochopen\u00ED slo\u017Eit\u00E9 biologie MM vneslo do l\u00E9\u010Dby p\u016Fsobky se zcela nov\u00FDm, biologick\u00FDm \u00FA\u010Dinkem (thalidomid, bortezomib a lenalidomid) a s nov\u00FDmi terapeutick\u00FDmi ter\u010Di, zahrnuj\u00EDc\u00EDmi vedle bun\u011B\u010Dn\u00FDch mechanism\u016F i z\u00E1sah do interakc\u00ED n\u00E1dorov\u00FDch bun\u011Bk s mikroprost\u0159ed\u00EDm kostn\u00ED d\u0159en\u011B." . "Sou\u010Dasn\u00E9 mo\u017Enosti l\u00E9\u010Dby mnoho\u010Detn\u00E9ho myelomu" . . . "The presented review of increasing therapeutic options for multiple myeloma (MM) documents that important advances have been made particularly in the last decade. While in the 1980s MM was a variably progressive disease predictive of low quality of life and 2.5-3 -year survival, the current therapeutic options result in complete remission in about 50 % of patients with median overall survival of about 5 years, with 20 % of patients being likely to survive for more than 10 years. A better understanding of the complicated biology of MM resulted in novel biological therapies (thalidomide, bortezomib and lenalidomide) and novel therapy targets including not only cellular mechanisms but also interactions between tumor cells and the bone marrow microenvironment."@en . "RIV/61989592:15110/09:10224244!RIV12-MZ0-15110___" . "1"^^ . "supportive therapy; immunomodulatory therapy; stem cell transplantation; high-dose chemotherapy; conventional therapy; multiple myeloma"@en . "0862-8947" .